Cadila Healthcare is currently trading at Rs. 241.40, up by 7.05 points or 3.01% from its previous closing of Rs. 234.35 on the BSE.
The scrip opened at Rs. 236.65 and has touched a high and low of Rs. 242.40 and Rs. 236.65 respectively. So far 44522 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 370.00 on 03-Dec-2018 and a 52 week low of Rs. 206.45 on 22-Aug-2019.
Last one week high and low of the scrip stood at Rs. 242.40 and Rs. 219.00 respectively. The current market cap of the company is Rs. 24508.40 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.13% and 8.00% respectively.
Zydus Cadila has declared the second Phase III DREAM-D trials of Desidustat, an Investigational New Drug (IND) targeted at treating anemia in dialysis dependent CKD patients.
Desidustat is a novel, oral, HIF-PH inhibitor being developed for treating anemia in CKD patients. This Phase III DREAM-D study will be a multicenter (50- 60 sites in India), randomized, active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Epoetin for the treatment of anemia in patients with CKD who are on dialysis.
Cadila Healthcare is an India-based pharmaceutical company.